Nuvaira, Inc. develops innovative and groundbreaking therapies that aim to improve the lives of the more than 65 million people around the world with obstructive lung disease. Founded in 2008, Nuvaira was established to address clinical needs in the treatment of overactive airway nerves, a common disease feature of both COPD and asthma. Nuvaira is a privately held medical device company, headquartered in Minneapolis, Minnesota USA and has more than 75 patents issued and pending worldwide. The dNerva® Lung Denervation System is CE Mark approved. The dNerva® lung denervation system is under clinical investigation and is not commercially available in the USA.